Life Science
Click to enlarge
Home » Our Report Repository » Retinal Biologics Market Analysis and Forecast (2021-2028) with COVID Impact Analysis
Life Science
Life Sciences BPO Market Analysis and Forecast (2021-2028) with COVID Impact Analysis $ 3,475.00
Back to products
Life Science
Computer Vision in Healthcare Market Analysis and Forecast (2021-2028) with COVID Impact Analysis $ 3,475.00

Retinal Biologics Market Analysis and Forecast (2021-2028) with COVID Impact Analysis

$ 3,475.00

Retinal Biologics Market by Drug Class (TNF-α Inhibitor, VEGF-A Antagonist), By Retinal Disorder Type (Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Macular Hole, Uveitis, Others), By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Ophthalmology Clinics) and By Geography – COVID-19 Impact Analysis, Post COVID Analysis, Opportunities, Trends and Forecast from 2021 to 2028

Report Code: EB_LS_1078 | Page: 113 | Published Date: May 2021

Categories: ,
Description

The global Retinal Biologics market size was valued at $XX Million in 2020 and is expected to reach $XX Million by 2028 growing at the CAGR of 6.5% from 2021 to 2028. This growth is attributed to several macros and microeconomic factors such as

  • Rise in the number of diseases such as age-related macular degeneration (AMD) are the driving factor for Retinal Biologics
  • Driver 2

Further several factors restraining the market growth include

  • Restraining 1
  • Restraining 2

Collaborations and Alliances in the Retinal Biologics market are expected to generate higher avenues during the forecast period.

The COVID-19 pandemic has led to supply chain disruptions leading to supply shortages or lower demand in the Retinal Biologics market. The travel restrictions and social-distancing measures have resulted in a sharp drop in consumer and business spending and this pattern is to continue for some time. The end-user trend and preferences have changed due to the pandemic and have resulted in manufacturers, developers, and service providers adopting various strategies to stabilize the company.

 In terms of COVID 19 impact, the Retinal Biologics market report also includes the following data points:

  • Impact on Retinal Biologics market size
  • End-User Trend, Preferences, and Budget Impact
  • Regulatory Framework/Government Policies
  • Key Players Strategy to Tackle Negative Impact/Post-COVID Strategies
  • Opportunity in Retinal Biologics market

Key Insight in the report:

The global Retinal Biologics market report covers executive summary, market dynamics, COVID impact & post COVID scenario, market size and forecast, competitive intelligence, market positioning, and product offerings.

Our report covers extensive competitive intelligence which includes the following data points:

  • Business Overview
  • Business Segment Data
  • Financial Data
  • Product Segment Analysis and Specification
  • Recent Development and Company Strategy Analysis
  • SWOT Analysis

The report covers market sizing and forecasting at the country level as well as at the segment level. Retinal Biologics market is analyzed across the below-mentioned different segments:

  • Drug Class
    • TNF-α Inhibitor
    • VEGF-A Antagonist
  • Retinal Disorder Type
    • Age-related Macular Degeneration (AMD)
    • Diabetic Retinopathy (DR)
    • Diabetic Macular Edema (DME)
    • Macular Hole
    • Uveitis
    • Others
  • Distribution Channel
    • Hospitals
    • Retail Pharmacies
    • Specialty Ophthalmology Clinics

Retinal Biologics market is also analyzed across the below-mentioned regions/countries:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific
  • Rest of the World
    • South America
    • Middle East & Africa

Some of the key players in Retinal Biologics market include:

  • Novartis AG
  • Hoffmann La Roche Ltd
  • AbbVie Inc.
  • MeiraGTx Limited
  • OncoGene
  • Johnson & Johnson
  • Allergan
  • Bristol-Myers Squibb Company
  • Regeneron
  • Oxurion NV

REPORT CONTENT BRIEF:

  • High-level analysis of the current and future market trends and opportunities
  • Detailed analysis on current market drivers, restraining factors, and opportunities in the future
  • Retinal Biologics market estimates for 2021 and forecast from 2022 to 2028 with CAGR from 2021 to 2028.
  • Vendor market share analysis at each product level
  • Competitor analysis with a detailed insight into its product segment, financial strength, and strategies adopted.
  • Identifies key strategies adopted including product launches and developments, mergers and acquisitions, joint ventures, collaborations, and partnerships as well as funding has taken and investment is done, among others.

Target Audience

  • Manufacturers
  • Suppliers and traders
  • Government, associations, and industrial bodies
  • Investors and trade experts
  • Consulting Firms or Individual Consultant
  • Anyone interested in understanding the industry dynamics of Retinal Biologics market

For more details mail us at

Ask a question / additional requirement













    Press Release

    Table of Content

    Table of Content

    Chapter 1.   Executive Summary

     

    Chapter 2.   Scope of The Study

                         2.1.   Market Definition

                         2.2.   Scope of The Study

                                   2.2.1.   Objectives of Report

     

    Chapter 3.   Evolve BI Methodology

     

    Chapter 4.   Market Insights and Trends

                         4.1.   Supply/ Value Chain Analysis

                         4.2.   Porter’s Five Forces Analysis

                                   4.2.1.   Threat of New Entrants

                                   4.2.2.   Bargaining Power of Buyers

                                   4.2.3.   Bargaining Power of Suppliers

                                   4.2.4.   Threat of Substitutes

                                   4.2.5.   Industry Rivalry

                         4.3.   Impact of COVID-19 on Retinal Biologics Market

                                   4.3.1.   Impact on Market Size

                                   4.3.2.   End User Trend, Preferences and Budget Impact

                                   4.3.3.   Regulatory Framework/Government Policies

                                   4.3.4.   Key Players Strategy to Tackle Negative Impact

                                   4.3.5.   Opportunity Window

     

    Chapter 5.   Market Dynamics

                         5.1.   Introduction

                         5.2.   DRO Analysis

                                   5.2.1.   Drivers

                                   5.2.2.   Restraints

                                   5.2.3.   Opportunities

     

    Chapter 6.   Global Retinal Biologics Market, By Drug Class

                         6.1.   Introduction

                         6.2.   TNF-α Inhibitor      

                         6.3.   VEGF-A Antagonist

     

     

    Chapter 7.   Global Retinal Biologics Market, By Retinal Disorder Type

                         7.1.   Introduction

                         7.2.   Age-related Macular Degeneration (AMD)

                         7.3.   Diabetic Retinopathy (DR)

                         7.4.   Diabetic Macular Edema (DME)

                         7.5.   Macular Hole

                         7.6.   Uveitis

                         7.7.   Others

     

     

    Chapter 8.   Global Retinal Biologics Market, By Distribution Channel

                         8.1.   Introduction

                         8.2.   Hospitals

                         8.3.   Retail Pharmacies

                         8.4.   Specialty Ophthalmology Clinics

     

     

    Chapter 9.   Global Retinal Biologics Market, By Region

                         9.1.   Introduction

                         9.2.   North America

                                   9.2.1.   Introduction

                                   9.2.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                   9.2.3.   Market Size and Forecast, By Country, 2020 - 2028

                                   9.2.4.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                   9.2.5.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                   9.2.6.   Market Size and Forecast, By Distribution Channel, 2020 – 2028

                                   9.2.7.   US

                                                  9.2.7.1.   Introduction

                                                  9.2.7.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.2.7.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.2.7.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.2.7.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.2.8.   Canada

                                                  9.2.8.1.   Introduction

                                                  9.2.8.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.2.8.4.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.2.8.5.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.2.8.6.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                         9.3.   Europe

                                   9.3.1.   Introduction

                                   9.3.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                   9.3.3.   Market Size and Forecast, By Country, 2020 - 2028

                                   9.3.4.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                   9.3.5.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                   9.3.6.   Market Size and Forecast, By Distribution Channel, 2020 – 2028

                                   9.3.7.   Germany

                                                  9.3.7.1.   Introduction

                                                  9.3.7.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.3.7.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.3.7.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.3.7.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.3.8.   France

                                                  9.3.8.1.   Introduction

                                                  9.3.8.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.3.8.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.3.8.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.3.8.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.3.9.   UK

                                                  9.3.9.1.   Introduction

                                                  9.3.9.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.3.9.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.3.9.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.3.9.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.3.10.   Italy

                                                  9.3.10.1.   Introduction

                                                  9.3.10.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.3.10.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.3.10.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.3.10.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.3.11.   Rest of Europe

                                                  9.3.11.1.   Introduction

                                                  9.3.11.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.3.11.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.3.11.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.3.11.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                         9.4.   Asia-Pacific

                                   9.4.1.   Introduction

                                   9.4.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                   9.4.3.   Market Size and Forecast, By Country, 2020 - 2028

                                   9.4.4.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                   9.4.5.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                   9.4.7.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.4.8.   China

                                                  9.4.8.1.   Introduction

                                                  9.4.8.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.4.8.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.4.8.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.4.8.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.4.9.   India

                                                  9.4.9.1.   Introduction

                                                  9.4.9.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.4.9.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.4.9.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.4.9.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.4.10.   Japan

                                                  9.4.10.1.   Introduction

                                                  9.4.10.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.4.10.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.4.10.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.4.10.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.4.11.   South Korea

                                                  9.4.11.1.   Introduction

                                                  9.4.11.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.4.11.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.4.11.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.4.11.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.4.12.   Rest of Asia-Pacific

                                                  9.4.11.1.   Introduction

                                                  9.4.12.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.4.12.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.4.12.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.4.12.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                         9.5.   Rest of The World (RoW)

                                   9.5.1.   Introduction

                                   9.5.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                   9.5.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                   9.5.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                   9.5.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.5.6.   Market Size and Forecast, By Region, 2020 - 2028

                                   9.5.7.   South America

                                                  9.5.7.1.   Introduction

                                                  9.5.7.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.5.7.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.5.7.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.5.7.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

                                   9.5.8.   Middle East & Africa

                                                  9.5.8.1.   Introduction

                                                  9.5.8.2.   Driving Factors, Opportunity Analyzed and Key Trends

                                                  9.5.8.3.   Market Size and Forecast, By Drug Class, 2020 - 2028

                                                  9.5.8.4.   Market Size and Forecast, By Retinal Disorder Type, 2020 – 2028

                                                  9.5.8.5.   Market Size and Forecast, By Distribution Channel, 2020 - 2028

     

    Chapter 10.   Competitive Landscape

                         10.1.   Introduction

                         10.2.   Vendor Share Analysis, 2020/Key Players Positioning 2020

     

    Chapter 11.   Company Profiles

                         11.1.   Novartis AG

                                   11.1.1.   Business Overview

                                   11.1.2.   Financial Analysis

                                   11.1.3.   Product Portfolio

                                   11.1.4.   Recent Development and Strategies Adopted

                                   11.1.5.   SWOT Analysis

                         11.2.   F. Hoffmann La Roche Ltd

                                   11.2.1.   Business Overview

                                   11.2.2.   Financial Analysis

                                   11.2.3.   Product Portfolio

                                   11.2.4.   Recent Development and Strategies Adopted

                                   11.2.5.   SWOT Analysis

                         11.3.   AbbVie Inc.

                                   11.3.1.   Business Overview

                                   11.3.2.   Financial Analysis

                                   11.3.3.   Product Portfolio

                                   11.3.4.   Recent Development and Strategies Adopted

                                   11.3.5.   SWOT Analysis

                         11.4.   MeiraGTx Limited

                                   11.4.1.   Business Overview

                                   11.4.2.   Financial Analysis

                                   11.4.3.   Product Portfolio

                                   11.4.4.   Recent Development and Strategies Adopted

                                   11.4.5.   SWOT Analysis

                         11.5.   OncoGene

                                   11.5.1.   Business Overview

                                   11.5.2.   Financial Analysis

                                   11.5.3.   Product Portfolio

                                   11.5.4.   Recent Development and Strategies Adopted

                                   11.5.5.   SWOT Analysis

                         11.6.   Johnson & Johnson

                                   11.6.1.   Business Overview

                                   11.6.2.   Financial Analysis

                                   11.6.3.   Product Portfolio

                                   11.6.4.   Recent Development and Strategies Adopted

                                   11.6.5.   SWOT Analysis

                         11.7.   Allergan

                                   11.7.1.   Business Overview

                                   11.7.2.   Financial Analysis

                                   11.7.3.   Product Portfolio

                                   11.7.4.   Recent Development and Strategies Adopted

                                   11.7.5.   SWOT Analysis

                         11.8.   Bristol-Myers Squibb Company

                                   11.8.1.   Business Overview

                                   11.8.2.   Financial Analysis

                                   11.8.3.   Product Portfolio

                                   11.8.4.   Recent Development and Strategies Adopted

                                   11.8.5.   SWOT Analysis

                         11.9.   Regeneron

                                   11.9.1.   Business Overview

                                   11.9.2.   Financial Analysis

                                   11.9.3.   Product Portfolio

                                   11.9.4.   Recent Development and Strategies Adopted

                                   11.9.5.   SWOT Analysis

                         11.10.   Oxurion NV

                                   11.10.1.   Business Overview

                                   11.10.2.   Financial Analysis

                                   11.10.3.   Product Portfolio

                                   11.9.4.   Recent Development and Strategies Adopted

                                   11.9.5.   SWOT Analysis

     

    Chapter 12.   Key Takeaways

     

    Connect to Analyst

    Connect to Analyst













      Research Methodology

      Research Methodology

      Related products

      Life Science

      Blood Purification Equipment Market Analysis and Global Forecast (2021-2028) with COVID Impact Analysis

      $ 3,475.00

      Blood Purification Equipment Market By Product Type (Portable , Stationary), By Indication(Sepsis, Renal Diseases, Others), By End User(Hospitals and Clinics, Dialysis Centers, Others) and By Geography – COVID-19 Impact Analysis, Post COVID Analysis, Opportunities, Trends and Forecast from 2021 to 2028

      Report Code: EB_LS_315| Page: 165 | Published Date: March 2021
      Add to cart
      Quick view
      Life Science

      Proteinase K Market Analysis and Global Forecast (2020-2027) with COVID Impact Analysis

      $ 3,475.00
      Proteinase K Market By Type (Natural, Recombinant), Form Factor (Liquid, Powder, Tablet), End User (Bio-Pharmaceutical, Pharmaceutical, Academic and Research Centers, Hospitals, Contract Research Organization, Diagnostic Laboratories) and By Geography – COVID-19 Impact Analysis, Post COVID Analysis, Opportunities, Trends and Forecast from 2020 to 2027 Report Code: EB_LS_451 | Page: 124| Published Date: March 2021
      Add to cart
      Quick view
      Life Science

      Gene Therapy Cell Culture Media Market Analysis and Forecast (2021-2028) with COVID Impact Analysis

      $ 3,475.00

      Gene Therapy Cell Culture Media Market By Product Type (Media, Viral Vectors), By Application (Biotechnology & Pharmaceutical Industry, Research Laboratory, Academic Institute, Others) and By Geography – COVID-19 Impact Analysis, Post COVID Analysis, Opportunities, Trends and Forecast from 2021 to 2028

      Report Code: EB_LS_333| Page: 164 | Published Date: May 2021
      Add to cart
      Quick view
      Healthcare

      Global Heart Transplantation Market

      $ 3,475.00
      Heart Transplantation Market By Surgery Type (Total Artificial Heart, Biventricular Pacing, Heart Restraint Devices, Ventricular Assist Devices, Other) By End Use (Hospitals, Cardiac institutes, Research Centers, Laboratories, Other) and By Geography: Global Trends, Opportunities and Forecast – 2020 to 2027
      Add to cart
      Quick view
      Healthcare

      Global Electroencephalography (EEG) Equipment Market

      $ 3,475.00
      Electroencephalography (EEG) Equipment Market By Product (EEG Equipment, EEG Accessories) By Application (Diseases Diagnosis, Sleep Monitoring, Anesthesia Monitoring, Trauma & Surgery, Others) By End User (Hospitals, Diagnostic Centers, Surgical Centers, Research Laboratories, Others) and By Geography: Global trends, opportunities and forecast – 2020 to 2026
      Add to cart
      Quick view
      Life Science

      Oncology information systems Market Analysis and Global Forecast (2020-2028) with COVID Impact Analysis

      $ 3,475.00
      Oncology information systems Market By Application (Radiation Oncology, Medical Oncology, Surgical Oncology, ), By Product (Software, Services) and By Geography – COVID-19 Impact Analysis, Post COVID Analysis, Opportunities, Trends and Forecast from 2021 to 2028 Report Code: EB_LS_335| Page: 167 | Published Date: March 2021
      Add to cart
      Quick view
      Life Science

      Topical Pain Relief Market Analysis and Global Forecast (2021-2028) with COVID Impact Analysis

      $ 3,475.00

      Topical Pain Relief Market By Therapeutic Class (Non-opioids, Opioids), By Type (Prescription Pain Relief, Over-the-counter (OTC) Pain Relief), By Distribution Channel(Pharmacy & Drug Store, e-Commerce, Retail & Grocery Store) and By Geography – COVID-19 Impact Analysis, Post COVID Analysis, Opportunities, Trends and Forecast from 2021 to 2028

      Report Code: EB_LS_311| Page: 155 | Published Date: March 2021
      Add to cart
      Quick view
      Life Science

      Proteomics Market Analysis and Global Forecast (2021-2028) with COVID Impact Analysis

      $ 3,475.00
      Proteomics Market By Component (Instruments, Reagents, Services,), By Application (Drug Discovery, Diseases Diagnosis) and By Geography – COVID-19 Impact Analysis, Post COVID Analysis, Opportunities, Trends and Forecast from 2021 to 2028 Report Code: EB_LS_331 | Page: 162 | Published Date: March 2021
      Add to cart
      Quick view